Research programme: haemophilia and lysosomal therapeutics - REGiMMUNE

Drug Profile

Research programme: haemophilia and lysosomal therapeutics - REGiMMUNE

Alternative Names: RGI 5000

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator REGiMMUNE
  • Class Enzymes; Small molecules
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Haemophilia; Lysosomal storage diseases

Highest Development Phases

  • Preclinical Haemophilia; Lysosomal storage diseases

Most Recent Events

  • 22 Sep 2015 Preclinical trials in Haemophilia in Japan (unspecified route) before September 2015
  • 22 Sep 2015 Preclinical trials in Lysosomal storage diseases in Japan (unspecified route) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top